Physician profile
Dipty Mangla
NPI 1801124870
$10,731.21
in general payments reported to CMS, 2019-2025
30 companies · $1,407 in 2025
The $1,407 reported for 2025 was more than what 75% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,140 · 2020: $144 · 2021: $948 · 2022: $1,408 · 2023: $3,466 · 2024: $2,219 · 2025: $1,407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,642 · Food and Beverage: $3,449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,642.01 |
| Food and Beverage | $3,449.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,290.06 | 2021-2025 | Osteocool Rf Ablation System, Kyphon Express II Kyphopak Tray, Intellis Adaptivestim |
| Si-Bone, INC. | $1,468.71 | 2022-2024 | |
| Stryker Corporation | $1,074.33 | 2021-2023 | Spinejack, Vitoss |
| Boston Scientific Corporation | $893.66 | 2021-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Superion Indirect Decompression System |
| Medtronic USA, INC. | $846.15 | 2019-2020 | |
| Nevro Corp. | $580.95 | 2019-2024 | Senza |
| Pacira Pharmaceuticals Incorporated | $548.39 | 2023-2024 | Iovera, Zilretta |
| Vertos Medical, INC. | $428.87 | 2023-2024 | Mild Device Kit |
| Radius Health, INC. | $266.37 | 2019-2025 | Tymlos |
| Otsuka America Pharmaceutical, INC. | $248.56 | 2023-2025 | Rexulti, Nuedexta |
| Teva Pharmaceuticals USA, INC. | $167.88 | 2023-2025 | Austedo Xr, Austedo Xr |
| Sk Life Science, INC. | $118.02 | 2023 | Xcopri |
| Chiesi USA, INC. | $115.93 | 2021 | |
| Abbvie INC. | $113.46 | 2024 | |
| Medline Industries LP | $95.93 | 2024-2025 | Medline Industries, INC. |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $81.23 | 2025 | Senza |
| Zynex Medical, INC. | $77.75 | 2025 | Nexwave |
| Relievant Medsystems, INC. | $42.05 | 2023 | Intracept |
| Saluda Medical Americas, INC. | $41.27 | 2024-2025 | Evoke |
| Abbott Laboratories | $38.62 | 2022-2025 | Eterna |
| Bioventus LLC | $32.55 | 2022 | |
| Mml US, INC. | $26.51 | 2025 | Reactiv8 |
| Spr Therapeutics, INC | $21.96 | 2024 | Sprint Pns System |
| International Rehabilitative Sciences, INC | $21.89 | 2024 | Rs 4i Plus Sequential Stimulator |
| Biotronik Nro, INC. | $16.40 | 2025 | Prospera |
| Fidia Pharma USA INC. | $15.54 | 2023 | Hymovis |
| Flowonix Medical Incorporated | $15.49 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.02 | 2023 | Seglentis |
| Pacira Therapeutics, INC. | $14.75 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.91 | 2023 | Relistor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dipty Mangla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.